|1.||Winikoff, Beverly: 32 articles (09/2015 - 05/2004)|
|2.||Blum, Jennifer: 15 articles (01/2014 - 09/2005)|
|3.||Winikoff, B: 13 articles (01/2016 - 01/2000)|
|4.||Durocher, Jill: 11 articles (01/2015 - 09/2005)|
|5.||Gemzell-Danielsson, K: 10 articles (01/2016 - 02/2004)|
|6.||Creinin, Mitchell D: 10 articles (12/2008 - 02/2004)|
|7.||Alfirevic, Z: 10 articles (11/2008 - 01/2000)|
|8.||Gemzell-Danielsson, Kristina: 9 articles (06/2015 - 09/2003)|
|9.||Diop, Ayisha: 8 articles (09/2014 - 06/2009)|
|10.||Ho, Pak Chung: 8 articles (08/2009 - 11/2002)|
|1.||Duodenal Ulcer (Curling's Ulcer)
12/01/1996 - "The results of the randomized, double-blind, controlled trials show that misoprostol is the only antiulcer drug proven to be effective in the prevention of NSAID-induced gastric and duodenal ulcers as well as for reducing serious upper gastrointestinal complications (perforation and/or haemorrhage). "
11/11/1996 - "Misoprostol and H2 blockers were beneficial in the long-term prevention of duodenal ulcers; misoprostol or H2 blockers in the short-term prevention of duodenal ulcers remains to be confirmed."
11/01/1986 - "Irrespective of whether duodenal ulcer was healed or unhealed, significantly (p less than 0.01) more patients on misoprostol (50% at week 8) showed improvement (nil or mild as endpoint) than the placebo group. "
07/27/1999 - "Previous studies have shown that misoprostol is effective in reducing the incidence of gastric and duodenal ulcers as well as serious gastrointestinal complications. "
09/01/2000 - "Misoprostol, PPI, and double dose H2RA are effective in preventing chronic NSAID related endoscopic gastric and duodenal ulcers. "
07/27/1987 - "It is concluded that in humanitarian clinical trials, misoprostol was frequently associated with symptomatic relief, with improvement in UGI hemorrhage, or with endoscopic improvement in severe UGI disease that had proven refractory to available medical therapy."
02/01/2004 - "The 200 microg oral misoprostol compared with the 400 microg oral misoprostol given 10-16 hours before first trimester surgical abortions results in less pre-operative vaginal bleeding and in a statistically, although not clinically significant reduction in cervical dilatation."
07/01/2015 - "A single dose of vaginal misoprostol is effective in reducing hemorrhage during myomectomy."
03/01/2014 - "Assessment of sublingual misoprostol as first-line treatment for primary post-partum hemorrhage: results of a multicenter trial."
10/01/2009 - "To evaluate efficacy of misoprostol by intrauterine route for the prevention of the obstetrical hemorrhage and to know its effects collaterals. "
|3.||Stomach Ulcer (Gastric Ulcer)
01/01/1995 - "The efficacy of 400 micrograms misoprostol daily in the prevention of NSAID (non-steroidal anti-inflammatory drug)-induced gastric ulcer has been proven. "
11/11/1996 - "The use of misoprostol, but no that of H2 blockers, was beneficial in the prevention of NSAID-induced gastric ulcers. "
08/01/2004 - "Although misoprostol is slightly more effective in preventing gastric ulcers in these patients, PPIs are better tolerated. "
03/01/1990 - "Misoprostol has a disadvantageous safety profile relative to available agents but is effective in preventing NSAID-induced gastric ulcers. "
09/01/1989 - "Misoprostol has been shown to be an effective agent for the prevention of NSAID-induced gastric ulcers. "
09/06/2004 - "Maintenance of ulcer healing is significantly greater in those who receive ongoing PPI treatment compared with placebo, and adverse events and treatment withdrawals are fewer compared with their occurrence in persons treated with misoprostol. "
01/01/1992 - "Although therapy for patients with NSAID-induced ulcers or those at high risk of developing them is still a matter of debate, the current literature supports the use of misoprostol as the only drug effective for the prevention of both NSAID-induced gastric and duodenal ulceration. "
01/08/2001 - "That the Misoprostol Ulcer Complications Outcomes Safety Assessment (MUCOSA) trial found full-dose misoprostol to be more effective in ulcer prevention than it was in prevention of ulcer complications suggests that either many of the ulcer complications were related to H. "
01/01/1994 - "Misoprostol is superior to placebo in healing NSAID ulcers during continued NSAID treatment but there have been no comparative trials with other ulcer-healing drugs. "
03/01/2000 - "PPI have now been definitively shown to be more effective in the relief of symptoms and in the healing and prevention of ulcers/erosions than H2-antagonists and also better tolerated than misoprostol. "
01/01/2012 - "Clinical and operational evidence indicates that misoprostol is a safe and effective technology for addressing postpartum hemorrhage, a major cause of maternal death. "
09/01/2011 - "In recent two decades, misoprostol has approved to be an effective agent for termination of pregnancy in various gestation, cervical ripening, labor induction in term pregnancy, and possible management of postpartum hemorrhage. "
12/01/2007 - "A literature review was conducted to determine whether misoprostol is an effective treatment for postpartum hemorrhage (PPH) and in what dose. "
08/01/1999 - "Oral misoprostol administered in the third stage of labor reduced postpartum blood loss and might be effective in reducing incidence of postpartum hemorrhage."
08/01/1998 - "To investigate whether rectally administered misoprostol is an effective treatment for postpartum hemorrhage unresponsive to conventional first-line management. "
|3.||Mifepristone (RU 486)
|4.||Non-Steroidal Anti-Inflammatory Agents (NSAIDs)
|7.||Diclofenac (SR 38)
|2.||Cesarean Section (Caesarean Section)